NL8902301A - Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins. - Google Patents
Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins. Download PDFInfo
- Publication number
- NL8902301A NL8902301A NL8902301A NL8902301A NL8902301A NL 8902301 A NL8902301 A NL 8902301A NL 8902301 A NL8902301 A NL 8902301A NL 8902301 A NL8902301 A NL 8902301A NL 8902301 A NL8902301 A NL 8902301A
- Authority
- NL
- Netherlands
- Prior art keywords
- protein
- virus
- human parvovirus
- recombinant
- genetic information
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 84
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 81
- 241000702617 Human parvovirus B19 Species 0.000 title claims abstract description 70
- 238000003556 assay Methods 0.000 title claims description 26
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 229960005486 vaccine Drugs 0.000 title claims description 10
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 62
- 101710081079 Minor spike protein H Proteins 0.000 claims abstract description 60
- 101710197658 Capsid protein VP1 Proteins 0.000 claims abstract description 57
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims abstract description 57
- 101710108545 Viral protein 1 Proteins 0.000 claims abstract description 57
- 230000002068 genetic effect Effects 0.000 claims abstract description 45
- 239000002245 particle Substances 0.000 claims abstract description 17
- 239000013604 expression vector Substances 0.000 claims abstract description 12
- 238000002255 vaccination Methods 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims description 56
- 230000014509 gene expression Effects 0.000 claims description 47
- 241000256251 Spodoptera frugiperda Species 0.000 claims description 45
- 241000701447 unidentified baculovirus Species 0.000 claims description 39
- 238000013320 baculovirus expression vector system Methods 0.000 claims description 37
- 241000484121 Human parvovirus Species 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 9
- 238000010166 immunofluorescence Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000969 carrier Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 230000018883 protein targeting Effects 0.000 claims 2
- 239000013598 vector Substances 0.000 abstract description 13
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 238000003259 recombinant expression Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 38
- 241000238631 Hexapoda Species 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 238000011997 immunoflourescence assay Methods 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000003298 DNA probe Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 241000473945 Theria <moth genus> Species 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000009585 enzyme analysis Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 208000007985 Erythema Infectiosum Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101900151434 Human parvovirus B19 Minor capsid protein VP1 Proteins 0.000 description 2
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000256248 Spodoptera Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108010003087 parvovirus B19 capsid protein VP2 Proteins 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14323—Virus like particles [VLP]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8902301A NL8902301A (nl) | 1989-09-14 | 1989-09-14 | Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins. |
| PCT/NL1990/000130 WO1991004330A1 (en) | 1989-09-14 | 1990-09-11 | Human parvovirus b19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines |
| EP90914243A EP0491824B2 (de) | 1989-09-14 | 1990-09-11 | Menschliche parvovirus-b19-proteine und virusähnliche partikeln, deren herstellung sowie deren verwendung in diagnostischen tests und in impfstoffen |
| DE69019359T DE69019359T3 (de) | 1989-09-14 | 1990-09-11 | Menschliche parvovirus-b19-proteine und virusähnliche partikeln, deren herstellung sowie deren verwendung in diagnostischen tests und in impfstoffen. |
| ES90914243T ES2073036T5 (es) | 1989-09-14 | 1990-09-11 | Proteinas b19 de parpovirus humano y particulas de tipo virus, su produccion y su utilizacion en pruebas de diagnostico y vacunas. |
| DK90914243T DK0491824T4 (da) | 1989-09-14 | 1990-09-11 | Humane parvovirus B19-proteiner og viruslignende partikler, deres fremstilling og anvendelse til diagnostiske bestemmelser og vacciner |
| AT90914243T ATE122395T1 (de) | 1989-09-14 | 1990-09-11 | Menschliche parvovirus-b19-proteine und virusähnliche partikeln, deren herstellung sowie deren verwendung in diagnostischen tests und in impfstoffen. |
| US08/461,988 US6287815B1 (en) | 1989-09-14 | 1995-06-05 | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines |
| US08/465,557 US6379885B1 (en) | 1989-09-14 | 1995-06-05 | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines |
| US08/465,747 US6204044B1 (en) | 1989-09-14 | 1995-06-06 | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines |
| US09/948,234 US20020119527A1 (en) | 1989-09-14 | 2001-09-07 | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8902301 | 1989-09-14 | ||
| NL8902301A NL8902301A (nl) | 1989-09-14 | 1989-09-14 | Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8902301A true NL8902301A (nl) | 1991-04-02 |
Family
ID=19855310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8902301A NL8902301A (nl) | 1989-09-14 | 1989-09-14 | Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0491824B2 (de) |
| AT (1) | ATE122395T1 (de) |
| DE (1) | DE69019359T3 (de) |
| DK (1) | DK0491824T4 (de) |
| ES (1) | ES2073036T5 (de) |
| NL (1) | NL8902301A (de) |
| WO (1) | WO1991004330A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92298A (en) * | 1988-11-14 | 2001-04-30 | Us Secretary U S Dept Of Comme | Method for producing isolated empty b19 parvovirus capsids, introducing genes into cells utilizing the same, diagnostic assays for detecting parvovirus infection and an anti-parvovirus vaccine containing said capsids |
| US7476389B1 (en) * | 1991-07-19 | 2009-01-13 | The University Of Queensland | Papillomavirus vaccines |
| ES2048646B1 (es) * | 1992-04-15 | 1994-10-01 | Ercros Sa | Procedimiento para la obtencion de la proteina vp2 del virus de la peste equina africana (ahsv) |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| CA2175256A1 (en) * | 1993-10-28 | 1995-05-04 | Andrea Kern | Adeno-associated virus - its diagnostic use with early abortion |
| AU5103396A (en) * | 1995-03-08 | 1996-09-23 | Klaus Hedman | Method for the diagnosis of injections |
| ES2282998T3 (es) * | 1996-01-02 | 2007-10-16 | Institut Pasteur | Pseudo-particularmente viricas recombinadas y aplicaciomnes vacunales y antitumorales. |
| FR2771751B1 (fr) | 1997-12-03 | 2000-05-26 | Assist Publ Hopitaux De Paris | Erythrovirus et ses applications |
| US6238860B1 (en) | 1998-11-05 | 2001-05-29 | Dyax Corp. | Binding moieties for human parvovirus B19 |
| SE520177C2 (sv) * | 1998-11-24 | 2003-06-03 | Kristina Broliden | Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller |
| US6818612B2 (en) | 1998-11-24 | 2004-11-16 | Kristina Broliden | Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| US6743772B1 (en) | 1998-11-24 | 2004-06-01 | Kristina Broliden | Use of parovirus capsid particles in the inhibition of cell proliferation and migration |
| HU230244B1 (hu) | 2001-06-28 | 2015-11-30 | Novartis Vaccines And Diagnostics, Inc. | Diagnosztikai esszék a B19 parvovírushoz |
| CA2572129A1 (en) * | 2004-07-01 | 2006-01-12 | The Circle For The Promotion Of Science And Engineering | Viral particle-like construct and method of forming the same under physiological conditions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4971793A (en) * | 1988-05-09 | 1990-11-20 | Boyce Thompson Institute For Plant Research, Inc. | Subunit canine parvovirus vaccine |
-
1989
- 1989-09-14 NL NL8902301A patent/NL8902301A/nl not_active Application Discontinuation
-
1990
- 1990-09-11 WO PCT/NL1990/000130 patent/WO1991004330A1/en active IP Right Grant
- 1990-09-11 DE DE69019359T patent/DE69019359T3/de not_active Expired - Lifetime
- 1990-09-11 DK DK90914243T patent/DK0491824T4/da active
- 1990-09-11 ES ES90914243T patent/ES2073036T5/es not_active Expired - Lifetime
- 1990-09-11 EP EP90914243A patent/EP0491824B2/de not_active Expired - Lifetime
- 1990-09-11 AT AT90914243T patent/ATE122395T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69019359T3 (de) | 2006-09-07 |
| ES2073036T3 (es) | 1995-08-01 |
| DK0491824T3 (da) | 1995-07-17 |
| DK0491824T4 (da) | 2006-05-08 |
| ES2073036T5 (es) | 2006-08-01 |
| EP0491824B2 (de) | 2006-04-12 |
| ATE122395T1 (de) | 1995-05-15 |
| DE69019359T2 (de) | 1995-10-12 |
| DE69019359D1 (de) | 1995-06-14 |
| EP0491824B1 (de) | 1995-05-10 |
| WO1991004330A1 (en) | 1991-04-04 |
| EP0491824A1 (de) | 1992-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5916563A (en) | Parvovirus protein presenting capsids | |
| US6132732A (en) | Parvovirus capsids | |
| US5905040A (en) | Parvovirus empty capsids | |
| Rosenfeld et al. | Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. | |
| US5316910A (en) | Bioassay for influenza A and B nucleoprotein | |
| US5882652A (en) | Empty canine parvovirus capsids having CPV recombinant VP2 and vaccines having such capsids | |
| Gall et al. | Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes | |
| CA1331155C (en) | Baculovirus transfer vectors | |
| CA1275625C (en) | Virus vaccine | |
| Urakawa et al. | Bluetongue virus tubules made in insect cells by recombinant baculoviruses: expression of the NS1 gene of bluetongue virus serotype 10 | |
| EP3294329B1 (de) | Neuartige baculovirusvektoren und verfahren zur verwendung | |
| Anderson et al. | Peptides derived from the unique region of B19 parvovirus minor capsid protein elicitneutralizing antibodies in rabbits | |
| Li et al. | Characterization of self-assembled virus-like particles of human polyomavirus BK generated by recombinant baculoviruses | |
| Pensiero et al. | Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant | |
| Schmaljohn et al. | Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome | |
| US5498413A (en) | Recombinant subunit vaccine against porcine parvovirus | |
| NL8902301A (nl) | Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins. | |
| Loudon et al. | Expression of the outer capsid protein VP5 of two bluetongue viruses, and synthesis of chimeric double-shelled virus-like particles using combinations of recombinant baculoviruses | |
| Riley et al. | Expression of recombinant parvovirus NS1 protein by a baculovirus and application to serologic testing of rodents | |
| JP3061196B2 (ja) | パルボウイルスｂ１９の免疫学的に活性なペプチドまたはポリペプチド | |
| US6001371A (en) | Parvovirus capsids | |
| US6204044B1 (en) | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines | |
| US6287815B1 (en) | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines | |
| Kawase et al. | Modest truncation of the major capsid protein abrogates B19 parvovirus capsid formation | |
| US6274307B1 (en) | Immunologically active peptides or polypeptides from the parvovirus B19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| BV | The patent application has lapsed |